Brazil's regulatory agency Anvisa has proposed that medtech and pharmaceutical firms be required to take active steps to warn the health care system and identify alternative sources before halting any drug production that could disrupt critically needed medications. Currently, companies are required to give six months' notice before stopping manufacture or withdrawing a product from market. Anvisa has three months to turn the proposal into a draft regulation for formal public comment.

Related Summaries